GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nurix Therapeutics Inc (NAS:NRIX) » Definitions » ROC (Joel Greenblatt) %

Nurix Therapeutics (Nurix Therapeutics) ROC (Joel Greenblatt) % : -380.31% (As of Feb. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Nurix Therapeutics ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Nurix Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Feb. 2024 was -380.31%.

The historical rank and industry rank for Nurix Therapeutics's ROC (Joel Greenblatt) % or its related term are showing as below:

NRIX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1232.72   Med: -603.33   Max: -220.24
Current: -442.44

During the past 6 years, Nurix Therapeutics's highest ROC (Joel Greenblatt) % was -220.24%. The lowest was -1232.72%. And the median was -603.33%.

NRIX's ROC (Joel Greenblatt) % is ranked worse than
54.94% of 1467 companies
in the Biotechnology industry
Industry Median: -334.45 vs NRIX: -442.44

Nurix Therapeutics's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -9.40% per year.


Nurix Therapeutics ROC (Joel Greenblatt) % Historical Data

The historical data trend for Nurix Therapeutics's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nurix Therapeutics ROC (Joel Greenblatt) % Chart

Nurix Therapeutics Annual Data
Trend Nov18 Nov19 Nov20 Nov21 Nov22 Nov23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial -536.26 -1,232.72 -736.40 -670.40 -400.38

Nurix Therapeutics Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -590.99 -375.19 -592.29 -493.04 -380.31

Competitive Comparison of Nurix Therapeutics's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Nurix Therapeutics's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nurix Therapeutics's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nurix Therapeutics's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Nurix Therapeutics's ROC (Joel Greenblatt) % falls into.



Nurix Therapeutics ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Nov. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 7.595) - (15.317 + 48.098 + 16.054)
=-71.874

Working Capital(Q: Feb. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 6.976) - (16.737 + 46.077 + 17.499)
=-73.337

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Nurix Therapeutics for the quarter that ended in Feb. 2024 can be restated as:

ROC (Joel Greenblatt) %(Q: Feb. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Nov. 2023  Q: Feb. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-180.876/( ( (47.95 + max(-71.874, 0)) + (47.17 + max(-73.337, 0)) )/ 2 )
=-180.876/( ( 47.95 + 47.17 )/ 2 )
=-180.876/47.56
=-380.31 %

Note: The EBIT data used here is four times the quarterly (Feb. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nurix Therapeutics  (NAS:NRIX) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Nurix Therapeutics ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Nurix Therapeutics's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Nurix Therapeutics (Nurix Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
1700 Owens Street, Suite 205, San Francisco, CA, USA, 94158
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
Executives
Houte Hans Van officer: Chief Financial Officer C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO CA 94158
Christine Ring officer: General Counsel C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO CA 94158
Gwenn Hansen officer: Chief Scientific Officer C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO CA 94158
Stefani Wolff officer: EVP and COO C/O PRINCIPIA BIOPHARMA INC., 400 EAST JAMIE COURT, SUITE 302, SOUTH SAN FRANCISCO CA 94080
Edward C Saltzman director C/O NURIX THERAPEUTICS, 1700 OWENS STREET, SUITE 205, SAN FRANCISCO CA 94158
Paul M Silva director C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY ST, CAMBRIDGE MA 02139
Judith A Reinsdorf director C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Pierre Beaurang officer: Chief Business Officer C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO CA 94158
Clay B Siegall director 21823 30TH DR SE, BOTHELL WA 98021
Ponoi Capital, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Ponoi Ii Management, Llc 10 percent owner 1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129
Ponoi Capital Ii, Lp 10 percent owner 1700 OWENS STREET, STE 500, SAN FRANCISCO CA 94158
Column Group Gp, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group L P 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Ponoi Management, Llc 10 percent owner 1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129

Nurix Therapeutics (Nurix Therapeutics) Headlines

From GuruFocus

Nurix Therapeutics to Participate in Upcoming Investor Conferences

By Value_Insider Value_Insider 11-02-2022